FY2025 EPS Estimates for Alector Raised by Cantor Fitzgerald

Alector, Inc. (NASDAQ:ALEC) – Research analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for Alector in a report released on Monday, November 10th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will earn ($1.50) per share for the year, up from their previous estimate of ($1.63). Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share. Cantor Fitzgerald also issued estimates for Alector’s FY2026 earnings at ($0.73) EPS.

A number of other analysts have also recently commented on ALEC. Cowen cut shares of Alector to a “hold” rating in a research note on Wednesday, October 22nd. TD Cowen cut shares of Alector from a “buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Wall Street Zen downgraded shares of Alector from a “hold” rating to a “sell” rating in a research note on Friday, September 26th. BTIG Research cut Alector from a “buy” rating to a “neutral” rating in a report on Wednesday, October 22nd. Finally, William Blair downgraded Alector from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 22nd. One equities research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Alector currently has an average rating of “Reduce” and an average target price of $3.00.

Alector Price Performance

NASDAQ:ALEC opened at $1.36 on Wednesday. Alector has a 1-year low of $0.87 and a 1-year high of $6.05. The company has a current ratio of 3.76, a quick ratio of 3.76 and a debt-to-equity ratio of 0.17. The firm has a fifty day simple moving average of $2.55 and a 200 day simple moving average of $1.93. The stock has a market capitalization of $148.44 million, a PE ratio of -1.27 and a beta of 0.93.

Alector (NASDAQ:ALEC) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.08. Alector had a negative return on equity of 123.02% and a negative net margin of 156.03%.The firm had revenue of $3.26 million during the quarter, compared to the consensus estimate of $3.49 million. Alector has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Alector

A number of large investors have recently made changes to their positions in the company. Acadian Asset Management LLC boosted its stake in Alector by 39.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,440,661 shares of the company’s stock valued at $1,768,000 after purchasing an additional 410,205 shares during the period. Ieq Capital LLC acquired a new stake in shares of Alector during the first quarter worth $99,000. Jacobs Levy Equity Management Inc. boosted its position in shares of Alector by 25.9% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,334,032 shares of the company’s stock valued at $1,641,000 after acquiring an additional 274,341 shares during the period. Invesco Ltd. grew its stake in shares of Alector by 209.6% in the first quarter. Invesco Ltd. now owns 148,576 shares of the company’s stock valued at $183,000 after acquiring an additional 100,591 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC grew its stake in shares of Alector by 49.2% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 52,095 shares of the company’s stock valued at $73,000 after acquiring an additional 17,170 shares in the last quarter. Institutional investors own 85.83% of the company’s stock.

Insiders Place Their Bets

In other Alector news, Director Paula Hammond sold 14,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 26th. The shares were sold at an average price of $2.36, for a total transaction of $33,040.00. Following the completion of the sale, the director directly owned 74,909 shares in the company, valued at $176,785.24. This trade represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 9.70% of the stock is currently owned by corporate insiders.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.